<DOC>
	<DOCNO>NCT01490125</DOCNO>
	<brief_summary>This study assess effect QVA149 patient-reported dyspnea moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) patient .</brief_summary>
	<brief_title>The Effect QVA149 Patient Reported Dyspnea Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This study use multi-center , randomize , blind , double-dummy placebo control , three-period crossover design assess effect daily QVA149 q.d vs. placebo tiotropium 18 Î¼g q.d . term patient report dyspnea assess Baseline Dyspnea Index ( BDI ) /Transient Dyspnea Index ( TDI ) ( SAC version ) patient moderate severe COPD .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Patients moderate severe stable chronic obstructive pulmonary disease Smoking history 10 pack year Postbronchodilator Forced Expiratory Volume 1 second ( FEV1 ) 30 80 % Patients must able use computer mouse display mMRC grade &gt; 2 Patients history long QT syndrome Patients Type I uncontrolled Type II diabetes Patients COPD exacerbation respiratory tract infection within 6 week prior screen Patients history asthma Patients pulmonary lobectomy , lung volume reduction surgery , lung transplantation Patients concomitant pulmonary disease Patients require long term oxygen therapy ( &gt; 15 h day ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>Dyspnea</keyword>
	<keyword>QVA149</keyword>
	<keyword>tiotropium</keyword>
</DOC>